- Home
- LCFY vs ADIL Comparison
LCFY vs ADIL Comparison
Compare LCFY & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LCFY | ADIL |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 7.3M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LCFY | ADIL |
|---|---|---|
| Price | $2.58 | $5.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | 11.5K | ★ 69.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $0.13 |
| 52 Week High | $7.75 | $5.55 |
Technical Indicators
Market Signals| Indicator | LCFY | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 75.58 |
| Support Level | $2.50 | $1.63 |
| Resistance Level | $2.81 | N/A |
| Average True Range (ATR) | 0.14 | 0.58 |
| MACD | 0.06 | 0.15 |
| Stochastic Oscillator | 67.47 | 94.62 |
Price Performance
Historical ComparisonAbout LCFY Locafy Limited
Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.